Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US7875587B2 · kind B2 · utility
12Cited by
14References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 5, 2007 |
| Grant date | Jan 25, 2011 |
| Priority date | — |
| Expiry date | Mar 5, 2027 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T29/4935
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides peptide analogues which are antagonists of gastric inhibitory peptide (GIP). The peptides, based on GIP 1-42 include substitutions and/or modifications which have enhanced resistance to degradation by the enzyme dipeptidyl peptidase IV (DPP IV). The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.